Citric acid monohydrate 334mg/5ml / Potassium citrate monohydrate 550mg/5ml / Sodium citrate dihydrate 500mg/5ml oral solution
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Citric acid + Potassium citrate + Sodium citrate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 6 · 1943–2026
Showing the 50 most relevant studies, sorted by most relevant.
Baker B, Herforth C, Low J, et al.
2026
- Malus
- Acetic Acid
- Urolithiasis
PurposeTo evaluate the potential stone-preventative effects of apple cider vinegar (ACV) supplementation on 24-h urinary citrate, pH, and volume.MethodsWe performed a randomized crossover trial testing ACV, coconut water, lemon water, and orange soda. Participants were non-stone formers randomized to two of the four beverages. Participants consumed one assigned beverage daily for one week, underwent a two-week washout period, and then consumed the second assigned beverage. Three 24-h urine collections were planned: one baseline collection prior to beverage consumption, one following completion of the first treatment week, and one following completion of the second week.ResultsTwenty participants were enrolled. Eight were female. Six consumed ACV, six coconut water, eight lemon water, and six diet orange soda. ACV did not significantly change 24-h urinary parameters. Coconut water (+ 273.8 mg/24 h, 95% CI 67.9-480 mg/24 h) and lemon water (+ 167.7 mg/24 h, 95% CI 16-319 mg/24 h) were associated with increased urinary citrate. Effects on urine pH and volume were not significant in any treatment arms.ConclusionACV did not significantly change 24-h urine parameters. Coconut water and lemon water increased urinary citrate. Further study is necessary to validate these findings in a larger cohort. Registered with ClinicalTrials.gov (NCT04073719, 8/28/2019).
Abstract licence: CC BY
Köglberger P, Perschinka F, Klein SJ, et al.
2025
- Bicarbonates
- Citric Acid
- Anticoagulants
Li P, Yang X, Lang Y, et al.
2025
- Calcium Oxalate
- Urolithiasis
- Kidney Calculi
Attinger MC, von Felten S, Rodrigues CL, et al.
2025
- Magnesium Compounds
- Citric Acid
- Thyroxine
Li P, Li M, Yin W, et al.
2025
- Calcium
- Citric Acid
- Anticoagulants
D. Shepherd, P.B. Garland
Methods in Enzymology, 1969
Khashayar Sakhaee, Michael Nicar, Kathy Hill, et al.
Kidney International, 1983
Merschmann R, Burgmer C, Eckert GP, et al.
2025
- Potassium Chloride
- Potassium
- Magnesium
Hypertension represents a major risk factor for cardiovascular diseases. As a diet high in sodium chloride is associated with hypertension, so-called "blood pressure salts" are attracting increasing scientific interest. These are characterized by a partial replacement of sodium chloride by other salts, mainly potassium and magnesium compounds. The aim of this review is to evaluate the bioavailability of potassium and magnesium salts as dietary supplements and to identify potential sodium chloride substitutes. A literature search was conducted in the PubMed database using the PICO scheme. Randomized controlled trials in healthy adults investigating the bioavailability of defined potassium/magnesium salts were included. Potassium chloride and potassium citrate showed good bioavailability irrespective of the route of administration and dose. Magnesium citrate and magnesium chloride showed good bioavailability while magnesium oxide was poorly bioavailable. This may be partly due to its poor solubility in water. The results indicate that potassium chloride and potassium citrate as well as magnesium citrate and chloride are suitable for the use as salt substitutes and for increasing potassium and magnesium intake in addition to reducing sodium. Due to its poor water solubility and consequently low bioavailability magnesium oxide is less suitable.
Abstract licence: CC BY
Seema Gosavi, Rushikesh Nanaware
Asian Journal of Pharmaceutical Analysis, 2024
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.